{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T02:08:29Z","timestamp":1794449309877,"version":"4.9.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T00:00:00Z","timestamp":1522972800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13023-018-0791-9","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T15:13:17Z","timestamp":1524150797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Gene therapy in rare diseases: the benefits and challenges of developing a patient-centric registry for Strimvelis in ADA-SCID"],"prefix":"10.1186","volume":"13","author":[{"given":"Heide","family":"Stirnadel-Farrant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Kudari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Garman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Imrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bikramjit","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Giannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Gabaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambra","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Zancan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Aiuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Cicalese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Batta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Appleby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Davinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,6]]},"reference":[{"key":"791_CR1","unstructured":"Hershfield M. Adenosine Deaminase Deficiency. NCBI Bookshelf: University of Washington, Seattle; 1993\u20132017."},{"key":"791_CR2","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1001\/jama.2014.9132","volume":"312","author":"A Kwan","year":"2014","unstructured":"Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312:729\u201338.","journal-title":"JAMA"},{"key":"791_CR3","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s00431-015-2518-4","volume":"174","author":"AP de Pagter","year":"2015","unstructured":"de Pagter AP, Bredius RG, Kuijpers TW, Tramper J, van der Burg M, van Montfrans J, et al. Overview of 15-year severe combined immunodeficiency in the Netherlands: towards newborn blood spot screening. Eur J Pediatr. 2015;174:1183\u20138.","journal-title":"Eur J Pediatr"},{"key":"791_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/BF00916954","volume":"8","author":"O Ryser","year":"1988","unstructured":"Ryser O, Morell A, Hitzig WH. Primary immunodeficiencies in Switzerland: first report of the national registry in adults and children. J Clin Immunol. 1988;8:479\u201385.","journal-title":"J Clin Immunol"},{"key":"791_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s10875-011-9609-4","volume":"32","author":"JW Verbsky","year":"2012","unstructured":"Verbsky JW, Baker MW, Grossman WJ, Hintermeyer M, Dasu T, Bonacci B, et al. Newborn screening for severe combined immunodeficiency; the Wisconsin experience (2008-2011). J Clin Immunol. 2012;32:82\u20138.","journal-title":"J Clin Immunol"},{"key":"791_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10875-014-0006-7","volume":"34","author":"BH Vogel","year":"2014","unstructured":"Vogel BH, Bonagura V, Weinberg GA, Ballow M, Isabelle J, DiAntonio L, et al. Newborn screening for SCID in New York state: experience from the first two years. J Clin Immunol. 2014;34:289\u2013303.","journal-title":"J Clin Immunol"},{"key":"791_CR7","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1399-3038.2007.00646.x","volume":"19","author":"A Yee","year":"2008","unstructured":"Yee A, De Ravin SS, Elliott E, Ziegler JB, Contributors to the Australian Paediatric Surveillance U. Severe combined immunodeficiency: a national surveillance study. Pediatr Allergy Immunol. 2008;19:298\u2013302.","journal-title":"Pediatr Allergy Immunol"},{"key":"791_CR8","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1182\/blood-2011-12-396879","volume":"120","author":"A Hassan","year":"2012","unstructured":"Hassan A, Booth C, Brightwell A, Allwood Z, Veys P, Rao K, et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood. 2012;120:3615\u201324. quiz 26","journal-title":"Blood"},{"key":"791_CR9","unstructured":"European Society for Blood and Marrow Transplantation (EBMT) European Society for Immunodeficiencies (ESID Inborn Errors Working Parties. EBMT\/ESID guidelines for haematopoietic stem cell transplantation for primary immunodeficiencies. 2017."},{"key":"791_CR10","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.jaci.2014.06.021","volume":"134","author":"CC Dvorak","year":"2014","unstructured":"Dvorak CC, Hassan A, Slatter MA, Honig M, Lankester AC, Buckley RH, et al. Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency. J Allergy Clin Immunol. 2014;134:935\u201343. e15","journal-title":"J Allergy Clin Immunol"},{"key":"791_CR11","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s10875-015-0191-z","volume":"35","author":"R Baffelli","year":"2015","unstructured":"Baffelli R, Notarangelo LD, Imberti L, Hershfield MS, Serana F, Santisteban I, et al. Diagnosis, treatment and long-term follow up of patients with ADA deficiency: a single-center experience. J Clin Immunol. 2015;35:624\u201337.","journal-title":"J Clin Immunol"},{"key":"791_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.clim.2005.07.006","volume":"117","author":"B Chan","year":"2005","unstructured":"Chan B, Wara D, Bastian J, Hershfield MS, Bohnsack J, Azen CG, et al. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin Immunol. 2005;117:133\u201343.","journal-title":"Clin Immunol"},{"key":"791_CR13","doi-asserted-by":"publisher","first-page":"7713","DOI":"10.4049\/jimmunol.1001770","volume":"185","author":"F Serana","year":"2010","unstructured":"Serana F, Sottini A, Chiarini M, Zanotti C, Ghidini C, Lanfranchi A, et al. The different extent of B and T cell immune reconstitution after hematopoietic stem cell transplantation and enzyme replacement therapies in SCID patients with adenosine deaminase deficiency. J Immunol. 2010;185:7713\u201322.","journal-title":"J Immunol"},{"key":"791_CR14","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.1182\/blood-2009-06-189209","volume":"114","author":"HB Gaspar","year":"2009","unstructured":"Gaspar HB, Aiuti A, Porta F, Candotti F, Hershfield MS, Notarangelo LD. How I treat ADA deficiency. Blood. 2009;114:3524\u201332.","journal-title":"Blood"},{"key":"791_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2174\/156652312799789253","volume":"12","author":"CA Montiel-Equihua","year":"2012","unstructured":"Montiel-Equihua CA, Thrasher AJ, Gaspar HB. Gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency. Curr Gene Ther. 2012;12:57\u201365.","journal-title":"Curr Gene Ther"},{"key":"791_CR16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1126\/science.270.5235.475","volume":"270","author":"RM Blaese","year":"1995","unstructured":"Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, et al. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science. 1995;270:475\u201380.","journal-title":"Science"},{"key":"791_CR17","unstructured":"GlaxoSmithKline. Strimvelis: Summary of Product Characteristics. European Medicines Agency. Last updated June 2016."},{"key":"791_CR18","doi-asserted-by":"crossref","unstructured":"Aiuti A, Roncarolo MG, Naldini L. Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products. EMBO Mol Med. 2017;9:237\u201340.","DOI":"10.15252\/emmm.201707573"},{"key":"791_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2016-01-688226","volume":"128","author":"MP Cicalese","year":"2016","unstructured":"Cicalese MP, Ferrua F, Castagnaro L, Pajno R, Barzaghi F, Giannelli S, et al. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. Blood. 2016;128:45\u201354.","journal-title":"Blood"},{"key":"791_CR20","doi-asserted-by":"crossref","unstructured":"Cicalese MP, Ferrua F, Castagnaro L, Rolfe K, De Boever E, Reinhardt RR, et al. Gene therapy for adenosine deaminase deficiency: a comprehensive evaluation of short- and medium-term safety. Mol Ther. 2018;26:917\u201331.","DOI":"10.1016\/j.ymthe.2017.12.022"},{"key":"791_CR21","unstructured":"Clinical Study ID AD1115611. ADA gene transfer into hematopoietic stem\/progenitor cells for the treatment of ADA-SCID [\n                    https:\/\/www.gsk-clinicalstudyregister.com\/study\/115611#ps\n                    \n                  ]. Accessed 3 Apr 2018."},{"key":"791_CR22","unstructured":"GlaxoSmithKline. GSK 2696273 clinical development program \u2013 median follow up \u2013 summary of clinical efficacy. Data on File. 2017;RD\/SVE\/0024\/17."},{"key":"791_CR23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s10875-017-0373-y","volume":"37","author":"DB Kohn","year":"2017","unstructured":"Kohn DB, Gaspar HB. How we manage adenosine deaminase-deficient severe combined immune deficiency (ADA SCID). J Clin Immunol. 2017;37:351\u20136.","journal-title":"J Clin Immunol"},{"key":"791_CR24","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1182\/blood-2012-02-400937","volume":"120","author":"F Candotti","year":"2012","unstructured":"Candotti F, Shaw KL, Muul L, Carbonaro D, Sokolic R, Choi C, et al. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood. 2012;120:3635\u201346.","journal-title":"Blood"},{"key":"791_CR25","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1126\/science.270.5235.470","volume":"270","author":"C Bordignon","year":"1995","unstructured":"Bordignon C, Notarangelo LD, Nobili N, Ferrari G, Casorati G, Panina P, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science. 1995;270:470\u20135.","journal-title":"Science"},{"key":"791_CR26","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1126\/science.1070104","volume":"296","author":"A Aiuti","year":"2002","unstructured":"Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410\u20133.","journal-title":"Science"},{"key":"791_CR27","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa0805817","volume":"360","author":"A Aiuti","year":"2009","unstructured":"Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009;360:447\u201358.","journal-title":"N Engl J Med"},{"key":"791_CR28","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ymthe.2006.06.007","volume":"14","author":"HB Gaspar","year":"2006","unstructured":"Gaspar HB, Bjorkegren E, Parsley K, Gilmour KC, King D, Sinclair J, et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther. 2006;14:505\u201313.","journal-title":"Mol Ther"},{"key":"791_CR29","first-page":"97ra80","volume":"3","author":"HB Gaspar","year":"2011","unstructured":"Gaspar HB, Cooray S, Gilmour KC, Parsley KL, Zhang F, Adams S, et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med. 2011;3:97ra80.","journal-title":"Sci Transl Med"},{"key":"791_CR30","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s10875-015-0157-1","volume":"35","author":"M Otsu","year":"2015","unstructured":"Otsu M, Yamada M, Nakajima S, Kida M, Maeyama Y, Hatano N, et al. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning. J Clin Immunol. 2015;35:384\u201398.","journal-title":"J Clin Immunol"},{"key":"791_CR31","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1172\/JCI35700","volume":"118","author":"S Hacein-Bey-Abina","year":"2008","unstructured":"Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118:3132\u201342.","journal-title":"J Clin Invest"},{"key":"791_CR32","first-page":"97ra79","volume":"3","author":"HB Gaspar","year":"2011","unstructured":"Gaspar HB, Cooray S, Gilmour KC, Parsley KL, Adams S, Howe SJ, et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med. 2011;3:97ra79.","journal-title":"Sci Transl Med"},{"key":"791_CR33","unstructured":"LMO2 associated clonal T cell proliferation 15 years after gamma-retrovirus mediated gene therapy for SCIDX1 [\n                    http:\/\/www.abstractsonline.com\/pp8\/#!\/4399\/presentation\/1820\n                    \n                  ]. Accessed 4 Apr 2018."},{"key":"791_CR34","doi-asserted-by":"publisher","first-page":"227ra33","DOI":"10.1126\/scitranslmed.3007280","volume":"6","author":"CJ Braun","year":"2014","unstructured":"Braun CJ, Boztug K, Paruzynski A, Witzel M, Schwarzer A, Rothe M, et al. Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. Sci Transl Med. 2014;6:227ra33.","journal-title":"Sci Transl Med"},{"key":"791_CR35","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.coi.2012.07.012","volume":"24","author":"A Aiuti","year":"2012","unstructured":"Aiuti A, Bacchetta R, Seger R, Villa A, Cavazzana-Calvo M. Gene therapy for primary immunodeficiencies: part 2. Curr Opin Immunol. 2012;24:585\u201391.","journal-title":"Curr Opin Immunol"},{"key":"791_CR36","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2174\/1566523215666150515145255","volume":"15","author":"U Siler","year":"2015","unstructured":"Siler U, Paruzynski A, Holtgreve-Grez H, Kuzmenko E, Koehl U, Renner ED, et al. Successful combination of sequential gene therapy and rescue Allo-HSCT in two children with X-CGD - importance of timing. Curr Gene Ther. 2015;15:416\u201327.","journal-title":"Curr Gene Ther."},{"key":"791_CR37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/mt.2010.232","volume":"19","author":"M Grez","year":"2011","unstructured":"Grez M, Reichenbach J, Schwable J, Seger R, Dinauer MC, Thrasher AJ. Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol Ther. 2011;19:28\u201335.","journal-title":"Mol Ther"},{"key":"791_CR38","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.clim.2014.10.003","volume":"156","author":"BM Jonkman-Berk","year":"2015","unstructured":"Jonkman-Berk BM, van den Berg JM, Ten Berge IJ, Bredius RG, Driessen GJ, Dalm VA, et al. Primary immunodeficiencies in the Netherlands: national patient data demonstrate the increased risk of malignancy. Clin Immunol. 2015;156:154\u201362.","journal-title":"Clin Immunol"},{"key":"791_CR39","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3389\/fimmu.2016.00365","volume":"7","author":"E Mortaz","year":"2016","unstructured":"Mortaz E, Tabarsi P, Mansouri D, Khosravi A, Garssen J, Velayati A, et al. Cancers related to Immunodeficiencies: update and perspectives. Front Immunol. 2016;7:365.","journal-title":"Front Immunol"},{"key":"791_CR40","first-page":"1263","volume":"28","author":"K Salavoura","year":"2008","unstructured":"Salavoura K, Kolialexi A, Tsangaris G, Mavrou A. Development of cancer in patients with primary immunodeficiencies. Anticancer Res. 2008;28:1263\u20139.","journal-title":"Anticancer Res"},{"key":"791_CR41","unstructured":"EMEA\/CHMP Guideline on safety and efficacy follow-up \u2013 risk management of advanced therapy medicinal products (EMEA\/149995\/2008) [\n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/10\/WC500006326.pdf.\n                    \n                  ]. Accessed 4 Apr 2018."},{"key":"791_CR42","unstructured":"EMEA\/CHMP\/GTWP\/60436\/2007 - Guideline on follow-up of patients adminstered with gene therapy medicinal products [\n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/11\/WC500013424.pdf\n                    \n                  ]. Accessed 4 Apr 2018."},{"key":"791_CR43","unstructured":"Registry list of diseases and genes [\n                    https:\/\/esid.org\/Working-Parties\/Registry\/New-ESID-Registry\/List-of-diseases-and-genes\n                    \n                  ]. Accessed 4 Apr 2018"},{"key":"791_CR44","unstructured":"United States Immunodeficiency Network (USIDNET); a program of the Immune Deficiency Foundation (IDF). Primary Immunodeficiency (PI) Diseases Registry at USIDNET. 2017."},{"key":"791_CR45","unstructured":"Agency for Healthcare Research and Quality. Registries for Evaluating Patient Outcomes: A User's Guide. Third edn. [\n                    https:\/\/effectivehealthcare.ahrq.gov\/topics\/registries-guide-3rd-edition\/research\/\n                    \n                  ]. Accessed 4 Apr 2018"},{"key":"791_CR46","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000444476","volume":"19","author":"A Coi","year":"2016","unstructured":"Coi A, Santoro M, Villaverde-Hueso A, Lipucci Di Paola M, Gainotti S, Taruscio D, et al. The quality of rare disease registries: evaluation and characterization. Public Health Genomics. 2016;19:108\u201315.","journal-title":"Public Health Genomics"},{"key":"791_CR47","unstructured":"Natural Histories Patient Registry [\n                    https:\/\/rarediseases.org\/for-industry\/education-research-programs\/natural-histories-patient-registry\/\n                    \n                  ]. Accessed 4 Apr 2018"},{"key":"791_CR48","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000365897","volume":"18","author":"D Taruscio","year":"2015","unstructured":"Taruscio D, Vittozzi L, Choquet R, Heimdal K, Iskrov G, Kodra Y, et al. National registries of rare diseases in Europe: an overview of the current situation and experiences. Public Health Genomics. 2015;18:20\u20135.","journal-title":"Public Health Genomics"},{"key":"791_CR49","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10545-017-0052-4","volume":"40","author":"R Penati","year":"2017","unstructured":"Penati R, Fumagalli F, Calbi V, Bernardo ME, Aiuti A. Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I. J Inherit Metab Dis. 2017;40:543\u201354.","journal-title":"J Inherit Metab Dis"},{"key":"791_CR50","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1002\/emmm.201202287","volume":"5","author":"KB Kaufmann","year":"2013","unstructured":"Kaufmann KB, Buning H, Galy A, Schambach A, Grez M. Gene therapy on the move. EMBO Mol Med. 2013;5:1642\u201361.","journal-title":"EMBO Mol Med."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0791-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-018-0791-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0791-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T23:16:25Z","timestamp":1554506185000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-018-0791-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,6]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["791"],"URL":"https:\/\/doi.org\/10.1186\/s13023-018-0791-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,6]]},"assertion":[{"value":"26 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SG works in the laboratories overseen by AA at SR-TIGET and is responsible for the performance and technical supervision of cellular assays conducted as part of the follow-up of patients with ADA-SCID treated with gene therapy.MK was an employee of GlaxoSmithKline, Brentford, Middlesex, UK at the time of the study. Currently an employee of Orchard Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"Ethical approval for the Strimvelis registry has been given by the San Raffaele Hospital Ethics Committee in Italy and will also be obtained where it is required in patients\u2019 own countries. All patients included in the registry are required to provide informed consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MPC is the Principal Investigator (PI) of the ADA-SCID registry trial. AA is the PI of the ADA-SCID gene therapy trial and other clinical trials sponsored by GlaxoSmithKline (GSK) which are part of the alliance between Ospedale San Raffaele-Telethon and GSK. SG, MG, AC and SZ declare no competing interest. MD is an employee of Pharmaceutical Product Development. HS-F, NG, JI, BC, RB, JA and PN are employees of GlaxoSmithKline. MK is an employee of Orchard Therapeutics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"49"}}